William Dawson

Abzena (Cambridge) Ltd. provides antibody engineering and immunogenicity screening services. The company was founded in 2004 and is headquartered in Babraham, the United Kingdom.

Part of Meridian Co., Ltd., Bionet Co., Ltd. develops and manufactures patient monitoring and fetal monitoring systems. The company is based in Seoul, South Korea. Bionet Co. was acquired by Meridian Co., Ltd. on June 24, 2003.

Novolytics Ltd. manufactures pharmaceutical preparations. The firm develops bacteriophage therapeutics. The company was founded on January 18, 2002 and is headquartered in Bolton, the Unite Kingdom.

The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists.

Eli Lilly & Co. Ltd. provides pharmaceutical health care solutions. It provide products for cardiovascular, dermatology, diabetes, endocrine, musculoskeletal, neuroscience, oncology and urology. The company was incorporated on April 9, 1963 and is headquartered in Basingstoke, the United Kingdom.

Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom.